ArticleFrontiers in oncology2026
Risk factors for radiation pneumonitis following adjuvant radiotherapy for breast cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To delineate the risk factors associated with radiation pneumonitis (RP) in breast cancer patients receiving adjuvant radiotherapy, thereby informing strategies for dosimetric optimization and risk mitigation. Methods: A retrospective analysis was performed on 811 female patients who underwent postoperative radiotherapy for breast cancer to investigate the potential risk factors associated with RP. Specifically, univariate analysis was employed to identify factors associated with RP, followed by multivariate logistic regression modeling to determine independent risk factors. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of identified risk factors, with diagnostic accuracy quantified by the area under the curve (AUC). Results: Univariate analysis demonstrated that the tumor stage, chest wall + supraclavicular + internal mammary lymph node irradiation (CSI), the number of chemotherapy cycles, the ipsilateral lung V Conclusions: The MLD, the number of chemotherapy cycles and CSI were confirmed as risk factors for RP. Bootstrap internal validation confirmed the robustness of these findings. Stringent dosimetric constraints to minimize MLD are imperative, particularly in patients with extended chemotherapy histories (≥ 7 cycles) undergoing CSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.